Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change

Less than a year after a major price cut in April, Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) is facing a 37.5% slash due to its dosage change for its main lung cancer indication under a new “quarterly re-pricing” rule introduced...read more